Document is current
Any future updates will be listed below
-
Authors
Silva, Milena
Wacker, David A.
Driver, Brian E.
Staugaitis, Abbey
Niedernhofer, Laura J.
Schmidt, Elizabeth L.
Kirkland, James L.
Tchkonia, Tamara
Evans, Tamara
Serrano, Carlos Hines
Ventz, Steffen
Koopmeiners, Joseph S.
Puskarich, Michael A. https://orcid.org/0000-0001-6358-4670
,
Akpa, Bimaje
Bhagat, Milind
Ingraham, Nicholas E.
Kesler, Sarah M.
Kubbara, Aahd
Mahan, Kathleen
Pendleton, Kathryn M.
Reilkoff, Ronald A.
Skolasinski, Steven
Thorp, Michael
- License Information
-
More Information
Article History
Received: 7 May 2024
Accepted: 16 September 2024
First Online: 21 October 2024
Declarations
:
: The protocol for this trial was centrally approved by the Advarra IRB (Protocol number Pro00070555) and subsequently approved by individual site IRBs (University of Minnesota—SITE00001869 which covers four of the participating hospitals; Hennepin County Medical Center—IRB-FY2023-660 which covers the fifth). Informed consent documented either in writing or by e-consent per local institutional protocols will be obtained from all participants.
: Not applicable. We do not anticipate publication of any details, images, or videos relating to any individual subjects.
: MS declares that she has no competing interests.DAW declares that he has no competing interests.BED declares that he has no competing interestsAS declares that she has no competing interests.ELS declares that she has no competing interests.LJN declares that she has no competing interests.TE declares that she has no competing interests.CHS declares that he has no competing interests.JSK declares that he has no competing interests.MAP declares he has no competing interests.SV is funded in part by a Medtronic faculty fellowship and an MSI data science seed grant; he declares that he has no other competing interests.JLK, TT, and Mayo Clinic, where JLK is an emeritus professor, hold patents related to senolytic agents.JLK holds no shares in companies developing senolytics. TT holds shares of Unity Biotechnology.Participation of JLK in this study is in compliance with Mayo Clinic’s conflict of interest policies.
